Daptomycin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Staphylococcal Skin Infections
Conditions
Staphylococcal Skin Infections
Trial Timeline
Jan 1, 2007 → —
NCT ID
NCT00463801About Daptomycin
Daptomycin is a approved stage product being developed by Novartis for Staphylococcal Skin Infections. The current trial status is terminated. This product is registered under clinical trial identifier NCT00463801. Target conditions include Staphylococcal Skin Infections.
What happened to similar drugs?
3 of 4 similar drugs in Staphylococcal Skin Infections were approved
Approved (3) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00463801 | Approved | Terminated |
Competing Products
20 competing products in Staphylococcal Skin Infections